| Autor: |
Solomon, Joshua J, Danoff, Sonye K, Woodhead, Felix A, Hurwitz, Shelley, Maurer, Rie, Glaspole, Ian, Dellaripa, Paul F, Gooptu, Bibek, Vassallo, Robert, Cox, P Gerard, Flaherty, Kevin R, Adamali, Huzaifa I, Gibbons, Michael A, Troy, Lauren, Forrest, Ian A, Lasky, Joseph A, Spencer, Lisa G, Golden, Jeffrey, Scholand, Mary Beth, Chaudhuri, Nazia, Perrella, Mark A, Lynch, David A, Chambers, Daniel C, Kolb, Martin, Spino, Cathie, Raghu, Ganesh, Goldberg, Hilary J, Rosas, Ivan O, Haynes-Harp, Shana, Poli, Fernando, Vidya, Coimbatore Sree, Baron, Rebecca R., Clouser, Timothy, Doyle, Tracy, Maeda, Anthony, Highland, Kristin B., Albayda, Jemima F., Collins, Sarah E., Suresh, Karthik S., Davis, John M., Limper, Andrew H., Amigues, Isabel, Eliopoulos, Kristina, Swigris, Jeffery J., Humphries, Stephen, Huntwork, John C., Glynn, Chris, Duncan, Steve R., Danila, Maria I., Glassberg, Marilyn K., Oberstein, Elana M., Belloli, Elizabeth A., Briggs, Linda, Nagaraja, Vivek, Cholewa, Linda, DiFranco, Donna, Green, Edward, Liffick, Christie, Naik, Tanvi, Montas, Genevieve, Lebiedz-Odrobina, Dorota, Bissell, Reba, Wener, Mark, Lancaster, Lisa H., Crawford, Leslie J., Chan, Karmela, Kaner, Robert J., Morris, Alicia, Wu, Xiaoping, Khalidi, Nader A., Ryerson, Christopher J., Wong, Alyson W., Fell, Charlene D., LeClercq, Sharon A., Hyman, Mark, Shapera, Shane, Mittoo, Shikha, Shaffu, Shireen, Gaffney, Karl, Wilson, Andrew M., Barratt, Shaney, Gunawardena, Harsha, Hoyles, Rachel K., David, Joel, Kewalramani, Namrata, Maher, Toby M., Molyneaux, Philip L., Kokosi, Maria A., Cates, Matthew J., Mandizha, Mandizha, Ashish, Abdul, Chelliah, Gladstone, Parfrey, Helen, Thillai, Muhunthan, Vila, Josephine, Fletcher, Sophie V., Beirne, Paul, Favager, Clair, Brown, Jo, Dawson, Julie K., Ortega, Pilar Rivera, Haque, Sahena, Watson, Pippa, Khoo, Jun K., Symons, Karen, Youssef, Peter, Mackintosh, John A. |
| Zdroj: |
The Lancet Respiratory Medicine; January 2023, Vol. 11 Issue: 1 p87-96, 10p |
| Abstrakt: |
Interstitial lung disease is a known complication of rheumatoid arthritis, with a lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety, tolerability, and efficacy of pirfenidone for the treatment of patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
